Tuesday, 9 September 2008

Michelle Obama 'Let People Connect' With Her Story, And Her Husband, Says 18-Year-Old DNC Delegate





Taylor Bates couldn't demand his eyes off Michelle Obama. Standing just feet from the massive Democratic National Convention stage in the Pepsi Center during Obama's closing address Monday night, with a clear up view of the first lady hopeful from his Vermont delegation's good seating in a first section to the left of the stage, the 18-year-old delegate was soaking in his first taste of the political big prison term ... and loving it.


"You see, Barack doesn't care where you're from, or what your background is, or what party, if any, you belong to," Obama said good the end of her speech. "He knows that thread that connects us � our belief in America's promise, our dedication to our children's future � is strong sufficiency to carry us unitedly as one and only nation, even when we disagree."


Bates, wHO will be a freshman at Tufts in the fall, has already logged more time in the political trenches than nigh of his fellow Green Mountain state compatriots. In addition to being in charge of managing the carbon offsets for the Vermont contingent, Bates is the Facebook president for all the young delegates at the convention and was an intern for Senator John Kerry's failed Democratic presidential campaign in 2004, as well as a U.S. Senate page in 2007.


Like many at the convention, Bates was inspired by Senator Obama's stirring 2004 DNC speech. In fact, while Michelle was telling the write up of her late father's struggles with multiple induration, Bates recalled how he turned to his father during Barack's speech in 2004 and predicted, "He's going to be chairman some day."


Signing a petition to nominate Obama, Bates listened as the candidate's spouse spun her story of growth up in a wage-earning family on Chicago's South Side. "Each one of us too comes here tonight by way of our possess improbable journey," Michelle aforesaid, echoing the oft-told story line of her husband's rise to the Democratic candidacy for president. "I come here tonight as a baby blessed with a brother who is my mentor, my shielder and my lifelong champion," she aforementioned of her 46-year-old sibling, Craig, world Health Organization introduced her.


"I think she's really connecting to a lot of people wHO don't needfully know her as good," Bates whispered, keeping one eye on the teleprompter so as not to miss whatever of the address. "The more people get to know them, the wagerer they like them, so I think this is really effective."


The young Democratic booster was in good company among Obama boosters in the building Monday night, wHO felt that something unprecedented was in the line. Wandering the concourse just moments before Michelle took the stage, filmmaker Spike Lee aforesaid there was only one reason he had set-aside a ticket to Denver this week. "To witness history ... history. ... That's what I'm here to see that we haven't seen before, history."


At a convention where the sometimes raw feelings of disappointed supporters of Senator Hillary Clinton can promptly and loudly rise to the open � such as the woman walking down fifteenth Street on Monday wHO busted into a shout of "Hillary!" when a bus touting Obama drove chisel by � Bates aforesaid Michelle Obama's shout-out to the other first noblewoman in her speech was a sign of the already-gelling party unity.


Speaking of the sacrifices of Americans from all stripes, the senator's married woman praised "citizenry like Hillary Clinton, wHO put those 18 meg cracks in the meth ceiling, so that our daughters and sons tin dream a little bigger and direct a little higher."


"People ar already approach together," aforesaid Bates, glad up at the multiple images of Michelle on the great screens around the way and applause hard in all the right places. "I recall that the fact that she's talking about the 18 one thousand thousand breaking the glass ceiling � she's just acknowledging that [Clinton supporters] have really made a difference and that they're already really behind us all the way."


As the presumptive Democratic candidate closed the night chatting with his wife and daughters via satellite link on the big silver screen in the main room, Bates huddled in a hallway deep within the Pepsi Center and gave his instantaneous take on how Mrs. Obama did.


"I think it was truly great how she emphasised her possess background, how she very tried to reach out to the Americans in the audience instead of just tolerant of repeating her husband's point, or instead of attacking the McCain campaign," he aforesaid. "She just now built up her have story and let mass connect with it, because she knows they volition. And it's really telling how she chose to do that when she had some different alternatives."









More info

Saturday, 30 August 2008

Mp3 music: No Fun At All






No Fun At All
   

Artist: No Fun At All: mp3 download


   Genre(s): 

Rock: Punk-Rock

   







No Fun At All's discography:


State of Flow
   

 State of Flow

   Year: 2003   

Tracks: 12
Master Celebrations
   

 Master Celebrations

   Year: 2003   

Tracks: 24
Throw It In
   

 Throw It In

   Year: 1997   

Tracks: 17
The Big Knockover
   

 The Big Knockover

   Year: 1997   

Tracks: 15
No Straight Angles
   

 No Straight Angles

   Year:    

Tracks: 15
EP's Going Steady
   

 EP's Going Steady

   Year:    

Tracks: 25






The Swedish hardcore ring No Fun at All formed in the small town of Skinnskatteberg during the summertime of 1991; light-emitting crystal rectifier by songwriter/guitarist Mikael Danielsson, the original lineup too included singer/drummer Jimmie Ohlsson and bassist Henrik Sunvisson. After completing the group's 1993 debut, Vision, Ohlsson exited to focus his wide-cut energies on his other band, Sober; with new frontman Ingemar Jansson, lead guitarist Krister Johansson, and drummer Kjell Ramstedt, No Fun at All returned in 1994 with No Straight Angles, followed a year by and by by Out of Bounds. In the rouse of 1997's The Big Knockover, Sunvisson throw in the towel the radical, with Danielsson assumptive bass duties; new second guitarist Stefan Neuman was installed in meter for 1999's Resilient in Tokyo. State of Flow followed in 2000, but it proved to be the band's final studio album. In 2003, NFAA's Swedish label, Burning Heart, united with American punk rocker stalwart Epitaph to release Master Celebrations, a fan-picked 24-track retrospective spanning the band's career.






Wednesday, 20 August 2008

Mental Health Issues Prominent In Child Soldiers


Compared to children in Nepal wHO were not forced into military
service, former child soldiers were more likely to present severe
mental health problems such as symptoms of posttraumatic stress
disorder (PTSD) and depression. These findings are reported in the
August 13 issue of JAMA.


As children continue to be ill-used by armed groups all over the
world, special mental wellness interventions for child soldiers are ever so
more necessary. There is, however, a paucity of research that
is consecrate to perusal the mental health of child soldiers in armed
conflicts. For several reasons, civilian children are more accessible
than child soldiers.


Researcher Brandon A. Kohrt (Emory University, Atlanta) and colleagues
set extinct to determine the mental health effects of both child soldiers
and children who were never strained into military service. The sample
consisted of 141 former baby soldiers and 141 never-conscripted
children in Nepal between March and April 2007. The children were
matched on historic period, sex, education Department, and ethnicity, and all participants
experient at least 1 type of trauma. The quondam child soldiers were
'tween 5 and 16 years old at time of conscription, and the modal age
of study participants was about 15.75 years old at the time of the
study.


Kohrt and colleagues set up that 75 of the child soldiers (52.3%) met
the symptom cutoff score for depression, 65 (46.1%) met the score for
anxiety, 78 (55.3%) met the criteria for PTSD, 55 (39%) met
the criteria for general psychological difficulties, and 88 (62.4%)
were functionally impaired. Statistically adjusting for traumatic
exposures and other possibly contradictory variables held that beingness a
child soldier was significantly associated with depression and PTSD
among girls (2.4 and 6.8 times higher odds, respectively) and PTSD
among boys (3.8 times higher betting odds). However, in that location was no statistical
connexion between beingness a baby soldier and general psychological
difficulties, anxiousness, or use impairment.


The authors note that, "The difference in mental health outcomes
between child soldiers and never-conscripted children can be explained
in part by greater exposure to traumatic events among child soldiers,
especially for general psychological difficulties and function
impairment."


"The study has several clinical and programmatic implications. First,
the greater burden of mental health problems among former child
soldiers supports the motive for focused programming, which should
include, but non consist entirely of, interventions to concentrate depression
symptoms and the psychological sequelae of psychic trauma, especially bombings
and torturing, as advantageously as incorporate belongingness and income
generation. Second, girl soldiers crataegus laevigata require focused attention,
perchance for factors not addressed in this study, such as problems of
sexual violence and reintegration difficulties. Third, the variation in
type and severity of mental health problems highlights the importance
of showing, including topically developed measures of function
impairment, as a base for intercession," suggest the researchers.


They reason: "Without screening there is a risk of infection of pathologizing
child soldiers as a group quite than providing support to those
individuals most impaired. Finally, the presence of mental health
problems among never-conscripted children illustrates the need for
comprehensive postconflict community-based psychosocial care non
restricted exclusively to child soldiers."


The Comparison of Mental Health Between Former Child Soldiers
and Children Never Conscripted by Armed Groups in Nepal
Brandon A. Kohrt, MA; Mark J. D. Jordans, MA; Wietse A. Tol,
MA; Rebecca A. Speckman, BA; Sujen M. Maharjan, BA; Carol M. Worthman,
PhD; Ivan H. Komproe, PhD

JAMA(2008).
300[6]: pp. 691-702.
Click
Here to View Abstract


Written by: Peter M Crosta


Copyright: Medical News Today

Not to be reproduced without permission of Medical News Today


More info

Sunday, 10 August 2008

ARIAD Announces Start Of Phase 2 Clinical Study Of Oral Deforolimus In Patients With Advanced Endometrial Cancer

�ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) proclaimed the origination of a randomized, multi-center, Phase 2 clinical trial to valuate the safety and efficaciousness of unwritten deforolimus, its investigational mTOR inhibitor, in patients with advanced endometrial cancer. In collaboration with Merck & Co. Inc., deforolimus is currently being studied in multiple clinical trials, both alone and in combination with other therapies, in patients with several different types of cancer. Under terms of the agreement, ARIAD will receive a $2.5 million milestone payment from Merck upon treating the first patient in this clinical study.


The clinical trial will compare single-agent oral deforolimus to progestin in patients with metastatic or repeated endometrial cancer following first line chemotherapy. The primary endpoint for the study is progression-free survival. Overall survival and response rate will be evaluated as secondary endpoints. This is the second Phase 2 clinical trial to begin this quarter examining the safety and efficacy of oral deforolimus in patients with different solid tumors.


"We make Phase 2 data on the endovenous form of deforolimus in endometrial crab and are pleased to now prove the potential difference of this drug prospect in its oral shape in alike patients with this crab," stated Pierre F. Dodion, senior vice president and chief medical officer of ARIAD. "There is substantial unmet aesculapian need for the efficacious treatment of patients with endometrial crab, and this controlled clinical study is designed to help inform us of the potentiality impact of oral deforolimus on patients with this difficult-to-treat crab."


The clinical trial will enroll 150 patients at approximately 50 sites including medical centers in North America, Europe, Asia and Australia. Patients will be randomized (1:1) to oral deforolimus or progestin, a usually accepted treatment in patients with endometrial cancer. Enrollment in the trial is expected to be completed by the second half of 2009.


"With the start of this trial, we today have begun enrollment in two Phase 2 clinical trials of oral deforolimus this quarter," said Harvey J. Berger, M.D., chair and headman executive ship's officer of ARIAD. "The begin of this study is another important milestone for deforolimus and for the joint development program with Merck. We are committed to complemental these clinical trials as quickly as possible facilitating the voltage development of deforolimus in multiple cancer indications."


ARIAD announced the initiation last month of a Phase 2 clinical trial of deforolimus in patients with advanced breast cancer.


For more selective information about clinical trials evaluating deforolimus, or to feel a trial site close to you, patients and physicians should call the US toll-free number 1-877-621-2302 or the international identification number 1-617-621-2302, or email us at ClinicalTrials@ariad.com. Additional information can also be launch at www.ClinicalTrials.gov.

About Endometrial Cancer


Endometrial cancer, which develops from the interior lining of the uterus, is the most coarse cancer found in the female reproductive system.


According to the American Cancer Society, about 40,one C new cases of endometrial cancer will be diagnosed in the United States and close to 7,470 women will die from this disease in 2008. Prognosis for patients is primarily based on the time of diagnosis relation to the stage of the cancer. Initial discourse consists of surgery alone, or in combination with radiation, chemotherapy and/or hormonal therapy. For those women with disease progression, chemotherapy is the only currently available treatment option, and limited benefit has been seen in such cases, emphasizing the need for new therapies.

About Deforolimus


ARIAD's lead product prospect, deforolimus, is a novel rapamycin analogue that specifically and potently inhibits mTOR, a downstream activator of the PI3K/Akt and food sensing pathways. The mTOR protein acts of the Apostles as a "master switch" in crab cells. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, part, metabolism, and angiogenesis. Multiple Phase 1 and 2 clinical trials of deforolimus in solid tumors and hematologic cancers have completed patient enrollment. The global Phase 3 SUCCEED trial of oral deforolimus in metastatic soft-tissue and bone sarcomas is based on a Special Protocol Assessment agreed upon by the U.S. Food and Drug Administration. ARIAD has a global partnership with Merck & Co., Inc. to develop and commercialize deforolimus, an investigational mTOR inhibitor, in patients with malignant neoplastic disease.

About ARIAD


ARIAD is engaged in the uncovering and evolution of breakthrough medicines to treat crab by regulating cell sign with small molecules. ARIAD is developing a comprehensive approach to patients with cancer that addresses the greatest medical need - aggressive and advanced-stage cancers for which current treatments are inadequate. ARIAD has a worldwide partnership with Merck & Co., Inc. to develop and commercialize deforolimus, ARIAD's lead cancer product nominee, which is in Phase 3 clinical development. ARIAD's second oncology product candidate, oral AP24534, is a novel multi-targeted kinase inhibitor in Phase 1 clinical development in hematological cancers. ARIAD has an single license to pioneering technology and patents related to certain NF-?B treatment methods, and the discovery and development of drugs to regulate NF-?B cell-signaling natural action, which may be useful in treating certain diseases. Additional information about ARIAD can be found on the web at hypertext transfer protocol://www.ariad.com.


This press spillage contains "innovative statements." Forward-looking statements are based on management's expectations and ar subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and public presentation to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, the costs associated with our research, development, manufacturing and other activities, the deal and results of preclinical and clinical studies of our product candidates, difficulties or delays in obtaining regulatory approvals to market place products resulting from our development efforts, our trust on our strategic partners and licensees and other key parties for the successful evolution, manufacturing and commercialization of products, the adequacy of our working capital resources and the availableness of additional funding, patent protection and third-party intellectual property claims relating to our and any partner's product candidates, the timing, scope, cost and outcome of legal and patent office proceeding concerning our NF-?B patent portfolio, the potential attainment of or other strategic transaction regarding the minority stockholders' interests in our 80%-owned underling, ARIAD Gene Therapeutics, Inc., future capital needs, risks related to key employees, markets, economical conditions, prices, reimbursement rates and competition, and other factors elaborate in the Company's public filings with the U.S. Securities and Exchange Commission. The selective information contained in this iron out release is believed to be stream as of the date of original issue. The Company does not signify to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in the Company's expectations, except as compulsory by law.

http://www.ariad.com


More info

Wednesday, 2 July 2008

Supergrass to release 'rockumentary'

Supergrass are to release a 'rockumentary' focusing on the club shows they performed as the Diamond Hoo Ha Men last year.

'Glange Fever' follows Gaz Coombes and Danny Goffey - in their guises as Randy and Duke - on their club tour of December 2007.

The two members performed mainly as a duo while bassist Mickey Quinn was recovering from a severe back injury, sustained when he sleepwalked out of a window while the band were recording their 'Diamond Hoo Ha' album in France.

'Glange Fever', some of which was streamed on NME.COM earlier this year, is out on DVD on August 4.




Aug 24, 2008 at Clapham Common, London -
More Supergrass tickets

Sunday, 22 June 2008

Dub War

Dub War   
Artist: Dub War

   Genre(s): 
Other
   Rock
   



Discography:


Pain   
 Pain

   Year: 1997   
Tracks: 10


Enemy Maker   
 Enemy Maker

   Year: 1995   
Tracks: 7


Wrong Side of Beautiful   
 Wrong Side of Beautiful

   Year:    
Tracks: 14




 





New York Governor Pardons Slick Rick

Saturday, 14 June 2008

Deerhoof reveal new album details

Deerhoof have revealed the details of their forthcoming album.

'Offend Maggie' -- the follow-up to 2007's 'Friend Opportunity' -- is due out in the US on October 7 via their longtime label Kill Rock Stars.

The 14-track album is divided into two "acts" and features songs including 'Fresh Born', Chandelier Searchlight' and 'Basket Ball Get Your Groove Back'.

The San Francisco band intend to launch an interactive website that will allow users to download and rearrange one of the tracks from the new album.

The album tracklisting is:

Act 1
'Offend Maggie'
'Fresh Born'
'Chandelier Searchlight'
'The Tears And Music of Love'
'Buck and Judy'
'Don�??t Get Born'
'My Purple Past
Act 2
'Basket Ball Get Your Groove Back'
'Numina'
'This Is God Speaking'
'Eaguru Guru'
'Snoopy Waves'
'Jagged Fruit'
'Family Of Others'

Deerhoof will announce a world tour of all-ages venues at low ticket prices this autumn. Meanwhile, the band are set to play the following live dates this summer:

Philadelphia, PA Festival Pier -- Roots Family Picnic (June 7)
Tokyo, Japan Liquidroom (14)
Osaka, Japan Shangri-la (15)
Nagoya, Japan Club Upset (16)
Sapporo, Japan Bessie Hall (18)
Brooklyn, NY Prospect Park (July 18)
Halifax, NS Marquee Club -- Halifax Jazz Festival (19)
Los Angeles, CA Hollywood Bowl KCRW World Festival (27)

--By our Los Angeles staff.
Find out more about NME.